class="info-alert">『Your web browser does not support JavaScript, but it does not affect browsing through the rest of the web site.』
jump to main content
:::

Industrial Technology Research Institute

search
close search window
:::

ITRI-501, an Anti-TIGIT Monoclonal Antibody for Solid Tumor Therapy

Technology Overview

ITRI-501, an Anti-TIGIT Monoclonal Antibody for Solid Tumor Therapy.
ITRI-501, an Anti-TIGIT Monoclonal Antibody for Solid Tumor Therapy.

ITRI has developed an anti-TIGIT immune checkpoint antibody, ITRI-501, which exhibits stronger natural killer and T-cell activation potencies than the competitor antibodies. In human TIGIT gene knock-in mouse syngeneic model, ITRI-501 alone is highly potent in inhibiting MC38 tumor cell growth. Cell line development and lab-scale process and formulation have been completed with manufacturability. PK and ADA method developments have been completed.

  • Features
    • ITRI-501 blocks CD155-TIGIT interaction and exhibits greater enhancement of T cell activation than other hits and reference antibodies.
    • ITRI-501 is non-immunogenic and recognizes a unique epitope of TIGIT.
    • ITRI-501 exhibits the strongest ADCC activity by human natural killer cells to kill TIGIT-expressing Treg-like tumor cells than the benchmark antibodies.
    • The affinity matured and effector function enhanced mouse surrogate, 2F1-LE6, exhibits strong single agent potency in inhibiting CT26 colorectal tumor cell growth in mouse syngeneic models, leading to long-term tumor-free survivors.
    • In human TIGIT gene knock-in mouse syngeneic model, ITRI-501 alone is highly potent in inhibiting MC38 tumor cell growth.
  • Specifications
    • Through side-by-side comparison with competitor’s anti-TIGIT biosimilars, including Roche (tiragolumab, 1D3), BMS (15A6), Arcus/Gilead (AB-154), BeiGene (BGB-A1217) and iTeos (EOS-488 mouse surrogate), we believe that ITRI-501 is the best-in-class anti-TIGIT monoclonal antibody.

Applications & Benefits

  • Cancer Immunotherapy, single or combination therapies.
ITRI-501 exhibits the strongest ADCC activity by human natural killer cells to kill TIGIT-expressing Treg-like tumor cells.
ITRI-501 exhibits the strongest ADCC activity by human natural killer cells to kill TIGIT-expressing Treg-like tumor cells.

Anti-tumor Efficacy in Syngeneic Mouse Models.
Anti-tumor Efficacy in Syngeneic Mouse Models.

Poster_ITRI-501, an Anti-TIGIT Monoclonal Antibody for Solid Tumor Therapy (PDF)

One-Stop Biomedical Services


One-Stop Biomedical Services

  • Listing Regulations Consulting: FDA/TFDA/CE application, medical device verification/export, medical device/medicine registration, IRB document organization, clinical trial application, and more.
  • Technology Transfer: Bio-IT, diagnostics and precision medicine technology, regeneration medicine technology, natural medicine and healthcare technology, targeted drug and delivery technology.
  • Model Translation: Domestic supply chain linkage, medical device design control, market analysis, strategy analysis of regulation in commercialization, and more.
  • Preclinical/Clinical Trial: Functional safety assessments, clinical research organization linkage, clinical evaluation and analysis, clinical trial planning, clinical trial analysis and reports.
  • Other Services: Quality system consulting, commercialization consulting, smart health solutions, software validation, medical device risk management, information security risk evaluation, technical documents preparation, business ecosystem linkage, and more.